Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

OncoCyte Corporation engages in the development and commercialization of proprietary laboratory-developed tests for the detection of cancer. The company offers DetermaRx, a molecular tests for early stage adenocarcinoma of the lung; and DetermaIO, a novel gene expression-based tests. It also develops DetermaDx, a non-invasive blood-based tests used to detect lung cancer. OncoCyte Corporation has a strategic collaboration with Guardian Research Network, Inc. to create a solution for pharma clients from patient recruitment to regulatory approvals. The company was founded in 2009 and is headquartered in Irvine, California.
Website: oncocyte.com


  • Bad financial results growth rate 0.0% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (41.7%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -52.5% (LTM)
  • Share price is 47.1% higher than minimum and 97.3% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 0.1x)
  • For the last 3 months insiders bought company shares on $7.2 mln (30.374% of cap.)

Key Financials (Download financials)

Ticker: OCX
Share price, USD:  (0.0%)3.06
year average price 3.15  


year start price 4.30 2023-07-06

max close price 4.52 2023-07-11

min close price 2.08 2023-11-08

current price 3.06 2024-07-04
Common stocks: 8 090 000

Dividend Yield:  0.0%
EV / Sales: 0.1x
Margin (EBITDA LTM / Revenue): -737.5%

Target EV / EBITDA (hist percentile): 0.1x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 25
Net Debt ($m): -24
EV (Enterprise Value): 1
EBITDA LTM (млн $): -59
Price to Book: 1.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-06-17prismmediawire.com

Oncocyte Appoints Andrea James as Chief Financial Officer

2024-06-03globenewswire.com

Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft Study

2024-05-30globenewswire.com

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

2023-11-09Seeking Alpha

OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript

2023-08-10Seeking Alpha

OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

2023-04-27GlobeNewsWire

Oncocyte To Announce First Quarter 2023 Financial Results

2023-04-1024/7 Wall Street

Broadwood Partners Now Owns 33.3% of OncoCyte
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol OCX OCX OCX OCX OCX OCX OCX OCX
reportedCurrency USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-31 2023-12-31 2023-11-09 2023-08-10 2023-05-15 2023-04-12 2022-11-10 2022-08-12
acceptedDate 2024-03-29 20:00:00 2023-12-29 19:00:00 2023-11-09 17:19:59 2023-08-10 16:50:24 2023-05-12 21:17:43 2023-04-12 16:54:07 2022-11-10 16:47:06 2022-08-11 19:08:43
calendarYear 2024 2023 2023 2023 2023 2022 2022 2022
period Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
revenue 176 000 314 000 429 000 463 000 297 000 -4M 1M 2M
costOfRevenue 511 000 409 000 181 000 191 000 287 000 -6M 2M 2M
grossProfit -335 000 -95 000 248 000 272 000 10000 2M -1M -314 000
grossProfitRatio -1.903 -0.303 0.578 0.587 0.034 -0.564 -1.154 -0.152
researchAndDevelopmentExpenses 2M 3M 2M 2M 2M -8M 4M 6M
generalAndAdministrativeExpenses 3M 2M 2M 4M 3M -3M 9M 8M
sellingAndMarketingExpenses 84 000 107 000 713 000 81 000 695 000 -589 000 407 000 691 000
sellingGeneralAndAdministrativeExpenses 4M 2M 3M 4M 4M -4M 9M 9M
otherExpenses 153 000 -22 000 -4000 -16 000 50 000 -371 000 0 0
operatingExpenses 5M 5M 5M 6M 6M -12M 14M 14M
costAndExpenses 6M 5M 6M 6M 7M -17M 16M 17M
interestIncome 0 0 117 000 1000 0 0 0 0
interestExpense 15 000 160 000 117 000 1000 10000 12 000 14 000 21 000
depreciationAndAmortization 335 000 325 000 426 000 5M 50 000 4M -4M 1M
ebitda -5M 4M -4M -3M -6M 13M -13M -7M
ebitdaratio -30.972 12.984 -8.559 -7.043 -20.788 -3.789 -13.152 -3.347
operatingIncome -6M -5M -7M -8M -6M 10M -9M -9M
operatingIncomeRatio -32.875 -15.917 -15.182 -17.914 -20.956 -2.727 -9.067 -4.142
totalOtherIncomeExpensesNet -3M -11M -1M -39 000 12M -369 000 -112 000 262 000
incomeBeforeTax -9M -16M -6M -8M 6M 9M -9M -8M
incomeBeforeTaxRatio -51.869 -50.93 -15.126 -17.998 20.064 -2.623 -9.177 -4.015
incomeTaxExpense 0 9M 922 000 0 3M 55M 112 000 0
netIncome -9M -16M -6M -8M 3M -45M -9M -8M
netIncomeRatio -51.869 -50.93 -15.126 -17.998 10.212 12.77 -9.287 -4.015
eps -1.1 -1.94 -0.79 -20.6 0.02 -0.41 -0.08 -0.07
epsdiluted -1.1 -1.94 -0.79 -20.6 0.02 -0.41 -0.08 -0.07
weightedAverageShsOut 8M 8M 8M 404 500 119M 111M 119M 113M
weightedAverageShsOutDil 8M 8M 8M 404 500 119M 111M 119M 113M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol OCX OCX OCX OCX OCX OCX OCX OCX
reportedCurrency USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-31 2023-12-31 2023-11-09 2023-08-10 2023-05-15 2023-04-12 2022-11-10 2022-08-12
acceptedDate 2024-03-29 20:00:00 2023-12-29 19:00:00 2023-11-09 17:19:59 2023-08-10 16:50:24 2023-05-12 21:17:43 2023-04-12 16:54:07 2022-11-10 16:47:06 2022-08-11 19:08:43
calendarYear 2024 2023 2023 2023 2023 2022 2022 2022
period Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 6M 9M 14M 17M 12M 20M 32M 45M
shortTermInvestments 0 0 441 000 530 000 553 000 433 000 419 000 579 000
cashAndShortTermInvestments 6M 9M 14M 18M 12M 20M 32M 45M
netReceivables 161 000 484 000 2M 2M 2M 2M 2M 2M
inventory 1 0 139 000 191 000 421 000 2M 0 0
otherCurrentAssets 796 000 782 000 672 000 1M 970 000 977 000 2M 2M
totalCurrentAssets 7M 11M 17M 21M 16M 26M 37M 49M
propertyPlantEquipmentNet 6M 5M 6M 8M 8M 11M 12M 12M
goodwill 0 0 0 0 0 0 19M 19M
intangibleAssets 57M 57M 57M 57M 57M 62M 88M 89M
goodwillAndIntangibleAssets 57M 57M 57M 57M 57M 62M 107M 108M
longTermInvestments 2M 2M 2M 2M 0 0 0 0
taxAssets 0 -1 -2M -2M 0 0 0 0
otherNonCurrentAssets 438 000 463 000 2M -6M 2M 2M 2M 2M
totalNonCurrentAssets 64M 64M 65M 59M 67M 75M 121M 122M
otherAssets 0 1 0 8M 0 0 0 0
totalAssets 71M 75M 82M 88M 83M 100M 157M 171M
accountPayables 908 000 953 000 1M 875 000 1M 1M 2M 2M
shortTermDebt 821 000 665 000 720 000 737 000 775 000 815 000 827 000 1M
taxPayables 0 0 0 0 0 0 0 0
deferredRevenue 0 0 6M -737 000 0 0 0 0
otherCurrentLiabilities 7M 6M 90 000 7M 7M 10M 10M 10M
totalCurrentLiabilities 8M 7M 8M 8M 9M 12M 13M 14M
longTermDebt 3M 2M 2M 2M 3M 3M 3M 3M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 43M 40M 34M 34M 33M 51M 65M 66M
totalNonCurrentLiabilities 46M 42M 36M 36M 35M 54M 68M 69M
otherLiabilities 0 0 0 0 0 0 0 0
capitalLeaseObligations 3M 3M 3M 3M 3M 4M 4M 4M
totalLiabilities 54M 49M 44M 44M 45M 66M 80M 83M
preferredStock 5M 5M 5M 5M 6M -39 000 5M 5M
commonStock 311M 310M 310M 310M 296M 295M 293M 290M
retainedEarnings -299M -290M -272M -266M -258M -261M -216M -206M
accumulatedOtherComprehensiveIncomeLoss 40 000 49 000 32 000 41 000 43 000 39 000 19 000 31 000
othertotalStockholdersEquity 0 0 -5M -5M -6M 39 000 -5M 0
totalStockholdersEquity 17M 26M 38M 44M 38M 34M 77M 88M
totalEquity 17M 26M 38M 44M 38M 34M 77M 88M
totalLiabilitiesAndStockholdersEquity 71M 75M 82M 88M 83M 100M 157M 171M
minorityInterest 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 71M 75M 82M 88M 83M 100M 157M 171M
totalInvestments 2M 2M 441 000 530 000 553 000 433 000 419 000 0
totalDebt 3M 3M 3M 3M 3M 4M 4M 5M
netDebt -2M -7M -11M -14M -8M -16M -28M -40M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol OCX OCX OCX OCX OCX OCX OCX OCX
reportedCurrency USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-31 2023-12-31 2023-11-09 2023-08-10 2023-05-15 2023-04-12 2022-11-10 2022-08-12
acceptedDate 2024-03-29 20:00:00 2023-12-30 19:00:00 2023-11-09 17:19:59 2023-08-10 16:50:24 2023-05-12 21:17:43 2023-04-12 16:54:07 2022-11-10 16:47:06 2022-08-11 19:08:43
calendarYear 2024 2023 2023 2023 2023 2022 2022 2022
period Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
netIncome -9M -16M -6M -8M 3M -45M -9M -8M
depreciationAndAmortization 335 000 325 000 426 000 457 000 472 000 1M 1M 1M
deferredIncomeTax 0 65 000 2M 24 000 0 0 0 0
stockBasedCompensation 464 000 611 000 608 000 834 000 834 000 3M 3M 2M
changeInWorkingCapital 1M -510 000 113 000 -2M -2M 407 000 -539 000 82 000
accountsReceivables 323 000 -21 000 -166 000 185 000 111 000 -22 000 -188 000 320 000
inventory 0 139 000 0 0 0 0 0 0
accountsPayables 854 000 -564 000 126 000 -2M -3M -125 000 183 000 260 000
otherWorkingCapital -158 000 -64 000 153 000 -137 000 3M 554 000 -534 000 -498 000
otherNonCashItems 3M 11M 1M 2M -12M 31M -6M -7M
netCashProvidedByOperatingActivities -4M -5M -2M -7M -10M -10M -11M -11M
investmentsInPropertyPlantAndEquipment -24 000 -264 000 -17 000 0 0 -802 000 -859 000 -1M
acquisitionsNet 0 0 231 000 123 000 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 367 000 0 0 0 0 0 0
otherInvestingActivites 0 138 000 -2M 0 0 0 0 0
netCashUsedForInvestingActivites -24 000 241 000 -1M 123 000 0 -802 000 -859 000 -1M
debtRepayment 0 -30 000 -30 000 -29 000 -28 000 -100 000 -572 000 -372 000
commonStockIssued 0 0 0 14M 0 -33M 0 33M
commonStockRepurchased 0 0 0 118 000 0 0 0 0
dividendsPaid 0 0 0 -118 000 0 0 0 0
otherFinancingActivites 0 0 -30 000 -2M 0 33M 0 4M
netCashUsedProvidedByFinancingActivities 0 -30 000 -30 000 12M -28 000 -100 000 -572 000 37M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0
netChangeInCash -4M -4M -4M 6M -10M -11M -13M 24M
cashAtEndOfPeriod 6M 11M 15M 19M 14M 23M 34M 47M
cashAtBeginningOfPeriod 9M 15M 19M 14M 23M 34M 47M 22M
operatingCashFlow -4M -5M -2M -7M -10M -10M -11M -11M
capitalExpenditure -24 000 -264 000 -17 000 0 0 -802 000 -859 000 -1M
freeCashFlow -4M -5M -2M -7M -10M -10M -12M -12M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2024 q1
2024-05-15 ET (fiscal 2024 q1)
2023 q4
2024-04-12 ET (fiscal 2023 q4)
2023 q3
2023-11-09 ET (fiscal 2023 q3)
2023 q2
2023-08-10 ET (fiscal 2023 q2)
2023 q1
2023-05-11 ET (fiscal 2023 q1)
2022 q4
2023-04-03 ET (fiscal 2022 q4)
2022 q3
2022-11-10 ET (fiscal 2022 q3)
2022 q2
2022-08-11 ET (fiscal 2022 q2)
2022 q1
2022-05-11 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-04-12 10:00 ET
Oncocyte Reports Full Year 2023 Financial Results
2024-04-12 01:46 ET
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
2024-04-11 21:30 ET
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
2024-04-09 20:05 ET
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results
2024-01-16 13:00 ET
Oncocyte to Present at the Sequire Investor Summit in Puerto Rico
2023-12-06 13:00 ET
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays
2023-11-09 12:00 ET
Oncocyte Reports Third Quarter 2023 Financial Results
2023-11-03 12:30 ET
Oncocyte to Announce Third Quarter 2023 Financial Results
2023-09-18 12:00 ET
Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier
2023-09-06 12:00 ET
Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-28 12:30 ET
Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage
2023-08-10 11:00 ET
Oncocyte Reports Second Quarter 2023 Financial Results
2023-08-09 12:00 ET
Oncocyte Regains Compliance With Nasdaq Listing Requirements
2023-08-08 12:30 ET
Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference
2023-08-03 12:00 ET
Oncocyte To Announce Second Quarter 2023 Financial Results
2023-07-25 13:08 ET
VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients
2023-07-24 17:35 ET
Oncocyte Announces 1-For-20 Reverse Stock Split
2023-06-27 12:30 ET
Oncocyte Begins Manufacturing Transplant Blood Test
2023-06-01 20:15 ET
Oncocyte Corporation to Present at the LD Micro Invitational XIII
2023-05-11 12:00 ET
Oncocyte Reports First Quarter 2023 Financial Results
2023-04-27 20:59 ET
Oncocyte To Announce First Quarter 2023 Financial Results
2023-04-18 12:45 ET
Oncocyte Presents New Data at AACR
2023-04-12 20:15 ET
Oncocyte Announces Reduction in Force
2023-04-07 12:24 ET
Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer
2023-04-03 12:00 ET
Oncocyte Pricing of $13.86 Million Public Offering of Common Stock
2023-03-31 21:00 ET
Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K
2023-03-29 20:01 ET
Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call
2023-03-15 20:01 ET
Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results
2023-03-02 14:00 ET
Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer
2023-02-22 13:00 ET
Oncocyte Completes Razor Genomics Transaction
2022-12-16 13:00 ET
Oncocyte Announces Initiatives to Focus Corporate Strategy
2022-11-30 23:05 ET
Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors
2022-11-30 23:00 ET
Oncocyte Announces Executive Leadership Changes
2022-11-10 21:30 ET
Oncocyte Reports Third Quarter 2022 Financial Results
2022-10-27 20:01 ET
Oncocyte to Announce Third Quarter 2022 Financial Results
2022-10-06 12:00 ET
DetermaIO™ Clinical Test to be used in SWOG Cancer Research Network Biomarker Study for Breast Cancer
2022-09-07 12:00 ET
Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on DetermaRx to CMS
2022-08-31 20:01 ET
Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference
2022-08-30 20:27 ET
Oncocyte Announces Five-Year VA Contract for DetermaRx
2022-08-24 12:00 ET
Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer
2022-08-10 20:05 ET
Oncocyte Reports Second Quarter 2022 Financial Results
2022-08-03 20:01 ET
Oncocyte to Participate at Upcoming Investor Conferences
2022-08-01 09:00 ET
Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022
2022-07-27 20:01 ET
Oncocyte to Announce Second Quarter 2022 Financial Results
2022-07-13 12:00 ET
Oncocyte Announces Market Entry and Early Adopter Program for Transplant Rejection Monitoring Business
2022-07-06 12:00 ET
Oncocyte Presents DetermaIO™ Data in Podium Presentation at ESMO World Congress on Gastrointestinal Cancer 2022
2022-06-22 12:00 ET
Oncocyte Hosting Key Opinion Webinar on the Role of DetermaIO and the Tumor Microenvironment in Clinical Practice
2022-05-26 21:00 ET
Oncocyte Presents DetermaIO™ Data at ASCO 2022 Supporting the Test’s Potential to Expand the Clinical Use of Immunotherapy
2022-05-11 20:05 ET
Oncocyte Reports First Quarter 2022 Financial Results
2022-05-05 12:00 ET
Oncocyte Completes Validation of TheraSure™ Transplant Monitor Test
2022-04-28 20:01 ET
Oncocyte to Announce First Quarter 2022 Financial Results
2022-04-27 20:30 ET
Oncocyte to Present New Data at ASCO 2022 Underpinning Pan-Cancer Clinical Utility of DetermaIO™
2022-04-14 02:01 ET
Oncocyte Corporation Announces Pricing of Public Offering of Common Stock and Warrants
2022-04-13 21:12 ET
Oncocyte Corporation Announces Proposed Public Offering of Common Stock and Warrants
2022-04-13 21:10 ET
Oncocyte Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferred Stock
2022-04-11 12:00 ET
Oncocyte Presents Confirmatory Data for DetermaIO™ at the American Association for Cancer Research Annual Meeting 2022
2022-03-28 12:00 ET
Oncocyte to Present New Data Confirming Association of IO Score with Response to Immunotherapy Treatment for Bladder Cancer at the American Association for Cancer Research Annual Meeting 2022
2022-03-10 21:05 ET
Oncocyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
2022-03-01 21:05 ET
Oncocyte to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday March 10
2022-02-10 13:00 ET
Oncocyte to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
2022-01-18 21:05 ET
Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision Oncology
2022-01-04 13:00 ET
Oncocyte Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI™ Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer
2021-12-09 23:00 ET
Spotlight Poster Presentation at San Antonio Breast Cancer Symposium SABCS 2021 Shows Oncocyte’s DetermaIO™ Clinical Test Predicts Response to Immunotherapy in Triple Negative Breast Cancer
2021-12-08 13:00 ET
Oncocyte and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled Distribution of DetermaRx™ in China
2021-12-06 13:00 ET
Oncocyte Corporation Hosting Business Update Call
2021-12-02 13:00 ET
Oncocyte to Present New Data on DetermaIO Clinical Test for Immunotherapy Response in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium 2021
2021-11-09 21:05 ET
Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update
2021-11-04 12:00 ET
Oncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction Test
2021-10-27 12:00 ET
Oncocyte Strengthens Transplant Intellectual Property Portfolio with US Patent Covering Digital PCR Technology for Early Detection of Organ Transplant Rejection
2021-10-26 20:05 ET
Oncocyte to Report Third Quarter 2021 Financial Results on Tuesday, November 9th
2021-10-07 12:00 ET
Oncocyte Appoints Gisela A. Paulsen as Chief Operating Officer
2021-09-30 12:00 ET
Oncocyte Publishes Study Demonstrating Predictive Potential for DetermaIO® Test in Triple Negative Breast Cancer
2021-09-20 15:35 ET
Oncocyte Announces Oral Presentation of New Data on Its DetermaIO™ Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting
2021-09-20 12:00 ET
Oncocyte Hosting Two-Part Key Opinion Leader Event Series
2021-09-16 12:00 ET
Modern Healthcare Recognizes Oncocyte as One of the 2021 Best Places to Work in Healthcare
2021-09-13 12:00 ET
Oncocyte to Present New Data on DetermaIO™ from NeoTRIPaPDL1 Trial in Oral Presentation from Late-Breaking Abstract at ESMO 2021
2021-09-07 20:05 ET
Oncocyte to Participate in the 5th Annual Lake Street Capital Markets Best Ideas Growth Conference
2021-08-17 12:00 ET
Oncocyte Launches First Real-World Evidence (RWE) Registry to Evaluate Biomarker Impact on Early-Stage Lung Cancer Treatment Decisions and Outcomes
2021-08-10 20:01 ET
Oncocyte Reports Second Quarter 2021 Financial Results and Provides Corporate Update
2021-08-09 12:00 ET
Oncocyte to Participate in Upcoming Investor Events
2021-07-27 14:35 ET
Oncocyte to Report Second Quarter 2021 Financial Results on Tuesday, August 10
2021-06-22 12:00 ET
Oncocyte Celebrates Women Thoracic Surgeons in #ShesMySurgeon Campaign
2021-06-03 12:00 ET
Oncocyte Announces Collaboration with Gruppo Oncologico del Nord Ovest to Evaluate Oncocyte’s DetermaIO Test in Colorectal Cancer, the Second Leading Cause of Cancer Mortality Globally
2021-06-01 12:00 ET
Oncocyte Selected as New “Day One” Launch Site for QIAGEN’s Companion Diagnostics Test to Identify Patients for Amgen’s Newly FDA-Approved Drug LUMAKRAS (Sotorasib) For Advanced Stage Lung Cancer
2021-05-17 20:01 ET
Oncocyte Reports First Quarter 2021 Financial Results and Provides Corporate Update
2021-05-06 12:00 ET
Medicare Coverage Determination for Molecular Testing Announced for Solid Organ Allograft Rejection, Citing Multiple Publications from OncoCyte Corporation’s Subsidiary Chronix Biomedical, Inc.
2021-05-04 20:01 ET
Oncocyte to Report First Quarter 2021 Financial Results on Monday, May 17
2021-04-28 20:31 ET
Oncocyte to Present New Data on DetermaIO™ Test as a Predictor of Immunotherapy Response in Renal Cell Cancer at the 2021 ASCO Annual Meeting
2021-04-19 12:00 ET
Oncocyte Enters the Rapidly Growing Immune Therapy Monitoring Market with the Closing of the Acquisition of Chronix Biomedical, Inc.
2021-04-14 13:02 ET
Oncocyte Hosting Key Opinion Leader Call on Novel Biomarkers in Identifying Appropriate Responders to Immune Checkpoint Inhibitors
2021-04-10 17:31 ET
Oncocyte Presents New Data at 2021 American Association for Cancer Research Annual Meeting Demonstrating Potential for Pan-Cancer Utility of DetermaIO™
2021-04-06 20:05 ET
Oncocyte to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare Conference
2021-03-16 20:01 ET
Oncocyte Provides Corporate Update and Reports Fourth Quarter and Annual 2020 Financial Results
2021-03-16 12:00 ET
Oncocyte Announces Peer-Reviewed Publication of Data Assessing Use of DetermaIO™ to Identify Patients Likely to Benefit from Immunotherapy Across Multiple Tumor Types
2021-03-15 12:00 ET
Oncocyte To Present New Data at 2021 American Association for Cancer Research (AACR) Annual Meeting Demonstrating Potential for Pan-Cancer Utility of DetermaIO™
2021-03-09 13:00 ET
Oncocyte Announces Formation of Medical Advisory Board
2021-03-04 13:00 ET
Oncocyte Announces Agreement with MultiPlan Network, Expanding Patient Access to DetermaRx™
2021-03-03 21:01 ET
Oncocyte to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 16
2021-02-25 13:00 ET
Oncocyte Closes Second Investment In Razor Genomics to Complete Acquisition
2021-02-23 21:05 ET
Oncocyte to Begin Trading on the Nasdaq Stock Market on March 8, 2021
2021-02-16 21:05 ET
Oncocyte to Participate in Fireside Chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
2021-02-09 21:05 ET
Oncocyte Announces Closing of $40 Million Public Offering of Common Stock
2021-02-05 13:25 ET
Oncocyte Announces Pricing of $35 Million Public Offering of Common Stock
2021-02-04 21:05 ET
Oncocyte Announces Proposed Public Offering of Common Stock
2021-02-02 13:00 ET
Oncocyte Announces Definitive Agreement to Acquire Chronix Biomedical, Inc.
2021-01-28 13:00 ET
Oncocyte to Present New Data at the IASLC 2020 World Conference on Lung Cancer
2021-01-20 21:08 ET
Oncocyte Announces $25 Million Registered Offering
2021-01-12 23:21 ET
Oncocyte to Present at the 23rd Annual Needham Virtual Growth Conference
2020-12-15 13:10 ET
Oncocyte to Present at the 15th Annual LD Micro Main Event
2020-12-15 13:00 ET
Oncocyte and Burning Rock Execute Strategic Agreement to Distribute DetermaRx in China
2020-12-15 06:33 ET
Burning Rock Announces an Exclusive in-Licensing of a Risk Stratification Test for Early Stage Lung-Cancer Patients from Oncocyte in China
2020-12-07 21:05 ET
Oncocyte Corporation Hosting Key Opinion Leader Call on Proprietary Molecular Tests for Cancer Treatment Selection
2020-11-18 21:05 ET
Oncocyte to Participate at 32nd Annual Piper Sandler Virtual Healthcare Conference
2020-11-18 13:00 ET
Oncocyte Presents New Data on Its DetermaIO™ Test at Association for Molecular Pathology (AMP) 2020 Conference
2020-11-12 21:05 ET
Oncocyte Reports Third Quarter 2020 Financial Results and Provides Corporate Update
2020-11-09 21:05 ET
Oncocyte to Present DetermaIO™ Test Data at the 2020 Society for Immunotherapy of Cancer (SITC) Conference
2020-11-02 13:00 ET
Oncocyte to Report Third Quarter 2020 Financial Results on Thursday, November 12
2020-10-28 12:00 ET
Oncocyte Named One of the 2020 Best Places to Work in Orange County in Its First Year in Irvine, CA
2020-10-20 21:21 ET
Oncocyte Announces Third Quarter Growth of DetermaRx™ Physician Adoption and Testing Volume
2020-10-14 12:00 ET
Oncocyte Announces New Prospective Data Demonstrating That Treatment Informed by DetermaRx™ Significantly Improves Lung Cancer Patient Survival
2020-10-08 12:00 ET
Oncocyte and Fondazione Michelangelo, a Leading Non-Profit Cancer Research Foundation, Announce Immune Therapy Biomarker Collaboration
2020-10-01 12:00 ET
Oncocyte Agrees to Enter Licensing and Collaboration Agreement with Chronix Biomedical
2020-09-14 12:00 ET
Oncocyte to Participate at the Lake Street Capital Markets 4th Annual Best Ideas Growth Conference
2020-09-09 12:00 ET
Oncocyte Receives Final Pricing Decision for DetermaRx™ Molecular Test for Lung Cancer from Centers for Medicare and Medicaid Services
2020-09-03 12:00 ET
Oncocyte and the Guardian Research Network® Announce Strategic Alliance
2020-09-01 15:00 ET
Oncocyte to Present at the LD 500 Virtual Conference
2020-08-27 12:00 ET
Oncocyte Announces Addition of Experienced Healthcare Executive, Jennifer Carter, MD, MPH, MBA to Board of Directors
2020-08-13 20:05 ET
Oncocyte to Participate at Needham Virtual Cancer Diagnostics Conference
2020-08-11 12:00 ET
Oncocyte to Hold KOL Webinar Highlighting Clinical Data on Its DetermaIO™ Test for Immunotherapy Response Prediction
2020-07-29 20:05 ET
Oncocyte Provides Corporate Update and Reports Second Quarter 2020 Financial Results
2020-07-28 12:00 ET
Oncocyte Announces Rapid Adoption of DetermaRx™ in Community Health Systems
2020-07-23 20:05 ET
Oncocyte to Hold KOL Webinar Showcasing New Data and Real World Usage of DetermaRx™
2020-07-20 20:05 ET
Oncocyte to Report Second Quarter 2020 Financial Results on Wednesday, July 29
2020-07-20 12:00 ET
Oncocyte Announces Final Local Coverage Determination from Noridian Healthcare Solutions for DetermaRx™, Securing National Medicare Payment for the Test Starting August 2020
2020-07-16 12:00 ET
Oncocyte Announces Distribution Agreement with ProGenetics Ltd, Expanding Commercial Availability of DetermaRx™ to Israel
2020-07-14 12:00 ET
Oncocyte Provides an Update on the Rapid Growth of DetermaRx™ Physician Adoption and Testing Volume
2020-06-29 20:05 ET
Oncocyte Announces Completion of DetermaDx™ Clinical Validation Study
2020-06-15 12:00 ET
Oncocyte Transitions to Revenue Generation as Multiple Payers Begin DetermaRx™ Reimbursements
2020-05-13 21:51 ET
Oncocyte Announces New Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting Demonstrating That the DetermaIO™ Gene Expression Test May Predict Response to Immunotherapy in Triple Negative Breast Cancer
2020-05-12 20:05 ET
Oncocyte Provides Corporate Update And Reports First Quarter 2020 Financial Results
2020-05-05 12:00 ET
Oncocyte Announces Peer-Reviewed Publication of Data Demonstrating the Potential of its TNBCType Assay to Inform Triple Negative Breast Cancer Drug Development
2020-05-05 12:00 ET
Oncocyte to Report First Quarter 2020 Financial Results on Tuesday, May 12
2020-05-01 12:00 ET
Oncocyte Announces the Publication of New Long-Term Patient Follow Up Data for DetermaRx™ and Research Describing the IRENE Cohort Being Used in the Development of DetermaDx™
2020-04-30 18:21 ET
Oncocyte Announces Final Medicare LCD from Palmetto for DetermaRx™
2020-04-24 12:00 ET
Oncocyte Announces $10.7 Million Registered Offering
2020-04-23 12:00 ET
Oncocyte Announces Distribution Agreement with CORE Diagnostics, Expanding Commercial Availability of DetermaRx™ to India, the Middle East and Africa
2020-04-07 12:00 ET
Oncocyte to Participate at 19th Annual Needham Virtual Healthcare Conference
2020-03-25 20:05 ET
ONCOCYTE PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS
2020-03-19 12:00 ET
Oncocyte Announces the Launch of CLIA-validated DetermaIO™, a Novel Gene Expression-Based Immune Therapy Response Predictor, for Research Use by Biopharmaceutical Companies and Researchers
2020-03-18 12:00 ET
ONCOCYTE TO REPORT FOURTH QUARTER AND FISCAL 2019 FINANCIAL RESULTS ON WEDNESDAY, MARCH 25
2020-02-05 13:00 ET
Oncocyte Closes Merger Agreement to Acquire Insight Genetics
2020-01-30 13:00 ET
Oncocyte Announces Relocation of its Headquarters to Orange County, California
2020-01-13 13:00 ET
Oncocyte Announces the Commercial Availability of DetermaRx™, the First Test for Chemotherapy Benefit Prediction in Patients with Early Stage Non-Small Cell Lung Cancer
2020-01-10 21:05 ET
Oncocyte Announces Definitive Agreement to Acquire Insight Genetics
2020-01-07 13:00 ET
OncoCyte Announces Successful Completion of CLIA Validation Study of DetermaDx™
2020-01-03 01:08 ET
OncoCyte Announces $7.6 Million Registered Offering
2019-11-27 13:00 ET
OncoCyte to Participate at Two Upcoming Investor Conferences in New York
2019-11-14 21:05 ET
OncoCyte Provides Corporate Update and Reports Third Quarter 2019 Financial Results
2019-11-11 17:15 ET
OncoCyte to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019
2019-11-08 13:00 ET
Oncocyte Announces Strategic Support of GO2 Foundation for Lung Cancer

SEC forms

Show financial reports only

SEC form 10
2024-05-15 00:00 ET
OncoCyte Corporation reported for 2024 q1
SEC form 8
2024-05-15 00:00 ET
OncoCyte Corporation published news for 2024 q1
SEC form 8
2024-05-15 00:00 ET
OncoCyte Corporation reported for 2024 q1
SEC form 10
2024-04-16 00:00 ET
OncoCyte Corporation reported for 2023 q4
SEC form 10
2023-11-09 17:19 ET
OncoCyte Corporation reported for 2023 q3
SEC form 10
2023-11-09 00:00 ET
OncoCyte Corporation reported for 2023 q3
SEC form 8
2023-11-09 00:00 ET
OncoCyte Corporation reported for 2023 q3
SEC form 10
2023-08-10 16:50 ET
OncoCyte Corporation reported for 2023 q2
SEC form 6
2023-08-10 07:05 ET
OncoCyte Corporation reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
OncoCyte Corporation reported for 2023 q2
SEC form 8
2023-08-10 00:00 ET
OncoCyte Corporation reported for 2023 q2
SEC form 6
2023-07-24 17:28 ET
OncoCyte Corporation published news for 2023 q2
SEC form 6
2023-07-14 06:03 ET
OncoCyte Corporation published news for 2023 q2
SEC form 6
2023-07-10 11:20 ET
OncoCyte Corporation published news for 2023 q2
SEC form 6
2023-06-30 16:14 ET
OncoCyte Corporation published news for 2023 q1
SEC form 6
2023-06-29 16:05 ET
OncoCyte Corporation published news for 2023 q1
SEC form 10
2023-05-15 00:00 ET
OncoCyte Corporation reported for 2023 q1
SEC form 6
2023-05-11 08:05 ET
OncoCyte Corporation reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
OncoCyte Corporation reported for 2023 q1
SEC form 6
2023-05-01 16:47 ET
OncoCyte Corporation published news for 2023 q1
SEC form 6
2023-04-13 16:50 ET
OncoCyte Corporation published news for 2023 q1
SEC form 10
2023-04-12 16:54 ET
OncoCyte Corporation reported for 2022 q4
SEC form 10
2023-04-12 00:00 ET
OncoCyte Corporation reported for 2022 q4
SEC form 6
2023-04-06 17:25 ET
OncoCyte Corporation published news for 2023 q1
SEC form 6
2023-04-05 09:00 ET
OncoCyte Corporation published news for 2023 q1
SEC form 8
2023-04-05 00:00 ET
OncoCyte Corporation published news for 2023 q1
SEC form 6
2023-03-31 18:02 ET
OncoCyte Corporation published news for 2022 q4
SEC form 6
2023-03-31 17:28 ET
OncoCyte Corporation reported for 2022 q4
SEC form 8
2023-03-31 00:00 ET
OncoCyte Corporation reported for 2022 q4
SEC form 6
2023-03-02 09:05 ET
OncoCyte Corporation published news for 2022 q4
SEC form 6
2023-02-23 17:00 ET
OncoCyte Corporation published news for 2022 q4
SEC form 6
2023-02-17 16:08 ET
OncoCyte Corporation published news for 2022 q4
SEC form 6
2023-02-13 16:07 ET
OncoCyte Corporation published news for 2022 q4
SEC form 6
2023-02-03 16:05 ET
OncoCyte Corporation published news for 2022 q4
SEC form 6
2023-01-30 16:05 ET
OncoCyte Corporation published news for 2022 q4
SEC form 6
2022-12-21 06:05 ET
OncoCyte Corporation published news for 2022 q3
SEC form 6
2022-12-05 16:05 ET
OncoCyte Corporation published news for 2022 q3
SEC form 6
2022-11-23 16:05 ET
OncoCyte Corporation published news for 2022 q3
SEC form 10
2022-11-10 16:47 ET
OncoCyte Corporation reported for 2022 q3
SEC form 6
2022-11-10 16:42 ET
OncoCyte Corporation published news for 2022 q3
SEC form 10
2022-11-10 00:00 ET
OncoCyte Corporation reported for 2022 q3
SEC form 8
2022-11-10 00:00 ET
OncoCyte Corporation reported for 2022 q3
SEC form 6
2022-11-09 16:06 ET
OncoCyte Corporation published news for 2022 q3
SEC form 6
2022-09-26 16:11 ET
OncoCyte Corporation published news for 2022 q2
SEC form 6
2022-08-15 16:16 ET
OncoCyte Corporation published news for 2022 q2
SEC form 10
2022-08-12 00:00 ET
OncoCyte Corporation reported for 2022 q2
SEC form 10
2022-08-11 19:08 ET
OncoCyte Corporation reported for 2022 q2
SEC form 6
2022-08-10 16:10 ET
OncoCyte Corporation published news for 2022 q2
SEC form 8
2022-08-10 00:00 ET
OncoCyte Corporation reported for 2022 q2
SEC form 6
2022-08-03 16:05 ET
OncoCyte Corporation published news for 2022 q2
SEC form 6
2022-08-01 08:05 ET
OncoCyte Corporation published news for 2022 q2
SEC form 6
2022-07-21 16:05 ET
OncoCyte Corporation published news for 2022 q2
SEC form 6
2022-07-15 08:00 ET
OncoCyte Corporation published news for 2022 q2
SEC form 6
2022-06-30 16:05 ET
OncoCyte Corporation published news for 2022 q1
SEC form 6
2022-06-08 16:05 ET
OncoCyte Corporation published news for 2022 q1
SEC form 6
2022-05-26 16:05 ET
OncoCyte Corporation published news for 2022 q1
SEC form 10
2022-05-12 16:27 ET
OncoCyte Corporation reported for 2022 q1
SEC form 10
2022-05-12 00:00 ET
OncoCyte Corporation reported for 2022 q1
SEC form 6
2022-05-11 16:11 ET
OncoCyte Corporation published news for 2022 q1
SEC form 8
2022-05-11 00:00 ET
OncoCyte Corporation reported for 2022 q1
SEC form 6
2022-05-02 16:05 ET
OncoCyte Corporation published news for 2022 q1
SEC form 6
2022-04-19 16:01 ET
OncoCyte Corporation published news for 2022 q1
SEC form 6
2022-04-13 17:09 ET
OncoCyte Corporation published news for 2022 q1
SEC form 6
2022-03-14 06:05 ET
OncoCyte Corporation published news for 2021 q4
SEC form 10
2022-03-11 17:17 ET
OncoCyte Corporation published news for 2021 q4
SEC form 10
2022-03-11 00:00 ET
OncoCyte Corporation published news for 2021 q4
SEC form 6
2022-03-10 16:10 ET
OncoCyte Corporation published news for 2021 q4
SEC form 8
2022-03-10 00:00 ET
OncoCyte Corporation published news for 2021 q4
SEC form 6
2022-01-18 16:19 ET
OncoCyte Corporation published news for 2021 q4
SEC form 6
2021-12-14 16:30 ET
OncoCyte Corporation published news for 2021 q3
SEC form 6
2021-12-08 08:05 ET
OncoCyte Corporation published news for 2021 q3
SEC form 10
2021-11-09 17:21 ET
OncoCyte Corporation published news for 2021 q3
SEC form 6
2021-11-09 16:37 ET
OncoCyte Corporation published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
OncoCyte Corporation published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
OncoCyte Corporation published news for 2021 q3
SEC form 6
2021-11-04 08:05 ET
OncoCyte Corporation published news for 2021 q3
SEC form 6
2021-10-27 08:05 ET
OncoCyte Corporation published news for 2021 q3
SEC form 6
2021-10-07 08:05 ET
OncoCyte Corporation published news for 2021 q3
SEC form 6
2021-09-20 11:40 ET
OncoCyte Corporation published news for 2021 q2
SEC form 10
2021-08-11 15:24 ET
OncoCyte Corporation published news for 2021 q2
SEC form 10
2021-08-11 00:00 ET
OncoCyte Corporation published news for 2021 q2
SEC form 6
2021-08-10 17:12 ET
OncoCyte Corporation published news for 2021 q2
SEC form 6
2021-07-20 16:47 ET
OncoCyte Corporation published news for 2021 q2
SEC form 6
2021-06-28 17:17 ET
OncoCyte Corporation published news for 2021 q1
SEC form 6
2021-06-24 08:00 ET
OncoCyte Corporation published news for 2021 q1
SEC form 6
2021-06-11 19:41 ET
OncoCyte Corporation published news for 2021 q1
SEC form 6
2021-06-01 16:25 ET
OncoCyte Corporation published news for 2021 q1
SEC form 6
2021-05-21 16:05 ET
OncoCyte Corporation published news for 2021 q1
SEC form 6
2021-05-21 08:00 ET
OncoCyte Corporation published news for 2021 q1
SEC form 6
2021-05-17 17:19 ET
OncoCyte Corporation published news for 2021 q1
SEC form 10
2021-05-17 16:06 ET
OncoCyte Corporation published news for 2021 q1
SEC form 10
2021-05-17 00:00 ET
OncoCyte Corporation published news for 2021 q1
SEC form 6
2021-05-10 08:00 ET
OncoCyte Corporation published news for 2021 q1
SEC form 6
2021-04-30 08:30 ET
OncoCyte Corporation published news for 2021 q1
SEC form 6
2021-04-19 13:44 ET
OncoCyte Corporation published news for 2021 q1
SEC form 10
2021-03-19 17:30 ET
OncoCyte Corporation published news for 2020 q4
SEC form 6
2021-03-16 16:36 ET
OncoCyte Corporation published news for 2020 q4
SEC form 6
2021-03-01 16:30 ET
OncoCyte Corporation published news for 2020 q4
SEC form 6
2021-02-25 08:00 ET
OncoCyte Corporation published news for 2020 q4
SEC form 6
2021-02-22 08:00 ET
OncoCyte Corporation published news for 2020 q4
SEC form 6
2021-02-05 17:15 ET
OncoCyte Corporation published news for 2020 q4
SEC form 6
2021-02-04 17:15 ET
OncoCyte Corporation published news for 2020 q4
SEC form 6
2021-02-03 09:07 ET
OncoCyte Corporation published news for 2020 q4
SEC form 6
2021-02-02 16:36 ET
OncoCyte Corporation published news for 2020 q4
SEC form 6
2021-01-21 08:24 ET
OncoCyte Corporation published news for 2020 q4
SEC form 6
2020-12-16 06:00 ET
OncoCyte Corporation published news for 2020 q3
SEC form 6
2020-11-30 09:00 ET
OncoCyte Corporation published news for 2020 q3
SEC form 10
2020-11-12 16:50 ET
OncoCyte Corporation published news for 2020 q3
SEC form 6
2020-11-12 16:30 ET
OncoCyte Corporation published news for 2020 q3